Cargando…

Design, Synthesis and Biochemical Evaluation of Novel Selective Estrogen Receptor Ligand Conjugates Incorporating an Endoxifen-Combretastatin Hybrid Scaffold

Nuclear-receptors are often overexpressed in tumours and can thereby be used as targets when designing novel selective chemotherapeutic agents. To date, many conjugates incorporating an estrogen receptor (ER) ligand have been synthesised in order to direct chemical agents to tissue sites containing...

Descripción completa

Detalles Bibliográficos
Autores principales:	Keely, Niall O., Carr, Miriam, Yassin, Bassem, Ana, Gloria, Lloyd, David G., Zisterer, Daniela, Meegan, Mary J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5344255/ https://www.ncbi.nlm.nih.gov/pubmed/28536383 http://dx.doi.org/10.3390/biomedicines4030015

Ejemplares similares

Novel Selective Estrogen Receptor Ligand Conjugates Incorporating Endoxifen-Combretastatin and Cyclofenil-Combretastatin Hybrid Scaffolds: Synthesis and Biochemical Evaluation
por: Kelly, Patrick M., et al.
Publicado: (2017)

Targeting Estrogen Receptor-Positive Breast Microtumors with Endoxifen-Conjugated, Hypoxia-Sensitive Polymersomes
por: Mamnoon, Babak, et al.
Publicado: (2021)

Anticancer Drug Conjugates Incorporating Estrogen Receptor Ligands
por: Zlotos, Darius P., et al.
Publicado: (2022)

Estrogen receptor-beta sensitizes breast cancer cells to the anti-estrogenic actions of endoxifen
por: Wu, Xianglin, et al.
Publicado: (2011)

Endoxifen and fulvestrant regulate estrogen-receptor α and related DEADbox proteins
por: Asberger, Jasmin, et al.
Publicado: (2020)

Synthesis and Antiproliferative Evaluation of 3-Chloroazetidin-2-ones with Antimitotic Activity: Heterocyclic Bridged Analogues of Combretastatin A-4
por: Malebari, Azizah M., et al.
Publicado: (2021)

Endoxifen, 4-Hydroxytamoxifen and an Estrogenic Derivative Modulate Estrogen Receptor Complex Mediated Apoptosis in Breast Cancer
por: Maximov, Philipp Y., et al.
Publicado: (2018)

Endoxifen’s Molecular Mechanisms of Action Are Concentration Dependent and Different than That of Other Anti-Estrogens
por: Hawse, John R., et al.
Publicado: (2013)

Endoxifen, a New Treatment Option for Mania: A Double‐Blind, Active‐Controlled Trial Demonstrates the Antimanic Efficacy of Endoxifen
por: Ahmad, A, et al.
Publicado: (2016)

Antitumor activity of Z-endoxifen in aromatase inhibitor-sensitive and aromatase inhibitor-resistant estrogen receptor-positive breast cancer
por: Jayaraman, Swaathi, et al.
Publicado: (2020)

Incorporating bazedoxifene/conjugated estrogens into the current paradigm of menopausal therapy
por: Komm, Barry S, et al.
Publicado: (2012)

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects
por: Dezentjé, V. O., et al.
Publicado: (2015)

Combretastatin A4/poly(L-glutamic acid)-graft-PEG conjugates self-assembled to nanoparticles
por: Ou, Yang, et al.
Publicado: (2018)

Influence of the Length and Positioning of the Antiestrogenic Side Chain of Endoxifen and 4-Hydroxytamoxifen on Gene Activation and Growth of Estrogen Receptor Positive Cancer Cells
por: Maximov, Philipp Y., et al.
Publicado: (2014)

Cytotoxicity Studies of Novel Combretastatin and Pterostilbene Derivatives
por: Jakubowska, Joanna, et al.
Publicado: (2014)

Combretastatin-Inspired Heterocycles as Antitubulin Anticancer Agents
por: Hura, Neha, et al.
Publicado: (2018)

The Masked Polar Group Incorporation (MPGI) Strategy in Drug Design: Effects of Nitrogen Substitutions on Combretastatin and Isocombretastatin Tubulin Inhibitors
por: González, Myriam, et al.
Publicado: (2019)

Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch
por: Binkhorst, Lisette, et al.
Publicado: (2015)

Orally administered endoxifen inhibits tumor growth in melanoma-bearing mice
por: Chen, Paul, et al.
Publicado: (2018)

Exposure–response analysis of endoxifen serum concentrations in early-breast cancer
por: Sanchez-Spitman, Anabel Beatriz, et al.
Publicado: (2020)

Topical Endoxifen for Mammographic Density Reduction—A Randomized Controlled Trial
por: Bäcklund, Magnus, et al.
Publicado: (2022)

3-Vinylazetidin-2-Ones: Synthesis, Antiproliferative and Tubulin Destabilizing Activity in MCF-7 and MDA-MB-231 Breast Cancer Cells
por: Wang, Shu, et al.
Publicado: (2019)

The Effects of a Novel Hormonal Breast Cancer Therapy, Endoxifen, on the Mouse Skeleton
por: Gingery, Anne, et al.
Publicado: (2014)

Real-World Long-Term Experience on Endoxifen in Bipolar Disorder with Psychotic Symptoms
por: Thanvi, Vikas
Publicado: (2022)

Novel indole-bearing combretastatin analogues as tubulin polymerization inhibitors
por: Kumar, Sunil, et al.
Publicado: (2013)

Combretastatin A4 disodium phosphate-induced myocardial injury
por: Tochinai, Ryota, et al.
Publicado: (2016)

Combretastatins: An Overview of Structure, Probable Mechanisms of Action and Potential Applications
por: Karatoprak, Gökçe Şeker, et al.
Publicado: (2020)

Fabrication of hybrid nanocomposite scaffolds by incorporating ligand-free hydroxyapatite nanoparticles into biodegradable polymer scaffolds and release studies
por: Farkas, Balazs, et al.
Publicado: (2015)

Transporting Antitumor Drug Tamoxifen and Its Metabolites, 4-Hydroxytamoxifen and Endoxifen by Chitosan Nanoparticles
por: Agudelo, Daniel, et al.
Publicado: (2013)

Cost-effectiveness of monitoring endoxifen levels in breast cancer patients adjuvantly treated with tamoxifen
por: van Nuland, M., et al.
Publicado: (2018)

Influence of probenecid on endoxifen systemic exposure in breast cancer patients on adjuvant tamoxifen treatment
por: Buck, Stefan A. J., et al.
Publicado: (2022)

PI3Kgamma Inhibitor Attenuates Immunosuppressive Effect of Poly(l‐Glutamic Acid)‐Combretastatin A4 Conjugate in Metastatic Breast Cancer
por: Qin, Hanjiao, et al.
Publicado: (2019)

Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
por: Griggs, J, et al.
Publicado: (2001)

The interaction with tubulin of a series of stilbenes based on combretastatin A-4.
por: Woods, J. A., et al.
Publicado: (1995)

The anti-angiogenic effect and novel mechanisms of action of Combretastatin A-4
por: Su, Min, et al.
Publicado: (2016)

Synthesis and Cytotoxic Activity of a New Group of Heterocyclic Analogues of the Combretastatins
por: Lipeeva, Alla V., et al.
Publicado: (2014)

The vascular disrupting agent combretastatin A-4 phosphate causes prolonged elevation of proteins involved in heme flux and function in resistant tumor cells
por: Dey, Sanchareeka, et al.
Publicado: (2017)

Curcumin for the Prevention of Epithelial-Mesenchymal Transition in Endoxifen-Treated MCF-7 Breast Cancer Cells
por: Paramita, P, et al.
Publicado: (2018)

(Z)-Endoxifen and Early Recurrence of Breast Cancer: An Explorative Analysis in a Prospective Brazilian Study
por: Almeida, Thais, et al.
Publicado: (2022)

In vivo and in vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug
por: Grosios, K, et al.
Publicado: (1999)

Cannot write session to /tmp/vufind_sessions/sess_u8d01t22tbrllk15jpsv6qtkma